TuHURA Biosciences (NASDAQ:HURA - Get Free Report) was upgraded by investment analysts at Brookline Capital Management to a "strong-buy" rating in a research report issued to clients and investors on Monday,Zacks.com reports. Brookline Capital Management also issued estimates for TuHURA Biosciences' Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.60) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.43) EPS and FY2029 earnings at $0.08 EPS.
HURA has been the topic of several other reports. Wall Street Zen lowered TuHURA Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 target price on shares of TuHURA Biosciences in a research report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, TuHURA Biosciences currently has an average rating of "Buy" and an average target price of $12.67.
Read Our Latest Analysis on HURA
TuHURA Biosciences Stock Performance
Shares of HURA stock traded down $0.07 on Monday, reaching $2.22. 2,950,027 shares of the company's stock traded hands, compared to its average volume of 259,785. TuHURA Biosciences has a 12-month low of $1.80 and a 12-month high of $7.93. The business's 50 day moving average price is $3.27 and its two-hundred day moving average price is $3.66.
TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02).
Institutional Trading of TuHURA Biosciences
Large investors have recently made changes to their positions in the stock. Accent Capital Management LLC bought a new stake in shares of TuHURA Biosciences during the 4th quarter worth about $29,000. TT Capital Management LLC bought a new stake in shares of TuHURA Biosciences during the 4th quarter worth about $41,000. Jefferies Financial Group Inc. bought a new stake in shares of TuHURA Biosciences during the 4th quarter worth about $54,000. Bank of America Corp DE bought a new stake in shares of TuHURA Biosciences during the 4th quarter worth about $59,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of TuHURA Biosciences during the 4th quarter worth about $61,000. Institutional investors own 0.62% of the company's stock.
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Featured Articles
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
